Ropinirole

How to order Ropinirole

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Ropinirole on Prescriptsy

Ropinirole is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Ropinirole is a non-ergot dopamine agonist used for the treatment of Parkinson's disease and moderate-to-severe restless legs syndrome (RLS).

It works by directly stimulating dopamine D2 and D3 receptors in the brain, mimicking the effects of the neurotransmitter dopamine, which is deficient in these conditions.

Ropinirole is available as immediate-release tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg, 5 mg) and prolonged-release tablets (2 mg, 4 mg, 8 mg).

It is a prescription-only medicine (POM) in the United Kingdom, available as a generic or under the brand name Requip (GlaxoSmithKline).

Parkinson's disease is the second most common neurodegenerative disorder, affecting approximately 153,000 people in the UK according to Parkinson's UK.

It results from progressive loss of dopamine-producing neurones in the substantia nigra, leading to motor symptoms including bradykinesia (slowness of movement), rigidity, resting tremor, and postural instability, as well as a range of non-motor symptoms.

Restless legs syndrome affects approximately 5% to 10% of the adult population, causing an irresistible urge to move the legs, typically accompanied by uncomfortable sensations that worsen at rest and in the evening or at night.

This page provides a comprehensive clinical guide to ropinirole, covering how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about ropinirole

Before reading further, please note these essential safety points.

• Ropinirole may cause impulse control disorders including pathological gambling, compulsive shopping, binge eating, and hypersexuality. Patients and carers should be alert to these behaviours and report them to the prescriber.
• Sudden onset of sleep may occur without warning. Do not drive if you experience sudden drowsiness and notify the DVLA.
• Do not stop ropinirole abruptly. Gradual dose reduction over 1 to 2 weeks is essential.
• Ropinirole may cause dizziness and low blood pressure, particularly when standing up. Stand slowly to reduce this risk.
• Tell your prescriber if you smoke or plan to stop smoking, as this affects ropinirole levels in the body.

Understanding Parkinson's disease

Parkinson's disease is a progressive neurodegenerative condition caused by the loss of dopamine-producing neurones in the substantia nigra pars compacta, a region of the midbrain.

Dopamine is a neurotransmitter critical for the regulation of movement, and its depletion in the basal ganglia circuit leads to the characteristic motor features of Parkinson's disease.

Bradykinesia (slowness and reduced amplitude of movement) is the defining feature and must be present for diagnosis.

Other motor features include muscular rigidity, resting tremor (typically a "pill-rolling" tremor of the hand), and postural instability (which tends to occur later in the disease).

Non-motor symptoms are also prominent and include depression, anxiety, cognitive impairment, sleep disturbances, autonomic dysfunction (constipation, urinary problems, orthostatic hypotension), pain, and fatigue.

The NICE guideline on Parkinson's disease (NG71) recommends that first-line treatment should be selected based on the patient's motor symptoms, lifestyle, and preferences.

The three main classes of initial treatment are levodopa (the most effective motor symptom treatment), dopamine agonists (including ropinirole), and monoamine oxidase B (MAO-B) inhibitors (such as rasagiline or selegiline).

Dopamine agonists are often chosen as initial monotherapy in younger patients to delay the need for levodopa and reduce the risk of levodopa-associated motor complications (wearing-off, on-off fluctuations, and dyskinesias), although NICE notes that levodopa should not be avoided simply due to concerns about motor complications.

Understanding restless legs syndrome

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder characterised by an irresistible urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations described as crawling, tingling, burning, aching, or an internal restlessness.

Symptoms characteristically worsen during periods of rest or inactivity and are partially or completely relieved by movement.

They follow a circadian pattern, typically worsening in the evening and at night, which can significantly disrupt sleep.

RLS ranges from mild (occasional symptoms that can be managed with lifestyle measures) to severe (nightly symptoms causing profound sleep deprivation and daytime impairment).

Secondary causes of RLS should be excluded before starting drug treatment.

Iron deficiency (serum ferritin below 75 micrograms per litre) is the most important reversible cause; iron supplementation may improve or resolve symptoms.

Other secondary causes include chronic kidney disease, pregnancy, and certain medicines (antihistamines, antidepressants, antipsychotics).

NICE CKS on restless legs syndrome advises that non-pharmacological measures (leg stretching, warm baths, massage, sleep hygiene, caffeine avoidance) should be tried first.

If pharmacological treatment is needed, a dopamine agonist such as ropinirole is a first-line option for moderate to severe RLS.

How ropinirole works

Ropinirole is a selective non-ergoline dopamine agonist. It binds to and activates dopamine D2 and D3 receptors in the brain.

In Parkinson's disease, the loss of nigrostriatal dopaminergic neurones leads to reduced dopaminergic stimulation of the striatum.

Ropinirole directly stimulates the post-synaptic dopamine receptors in the striatum, bypassing the degenerating pre-synaptic neurones. This compensates for the dopamine deficiency and improves motor function.

Unlike levodopa, ropinirole does not require conversion to dopamine by dopa decarboxylase, so its effectiveness is independent of the number of surviving dopaminergic neurones.

In restless legs syndrome, the pathophysiology involves dopaminergic dysfunction in the hypothalamic A11 dopaminergic cell group and the spinal cord.

Ropinirole is thought to alleviate symptoms by enhancing dopaminergic transmission in these descending pathways, reducing the abnormal sensory processing that produces the characteristic leg discomfort and urge to move.

Ropinirole is a non-ergoline dopamine agonist, which means it does not have the ergot-derived chemical structure of older dopamine agonists such as bromocriptine and cabergoline.

This is clinically important because ergot-derived dopamine agonists carry a risk of fibrotic reactions (cardiac valve fibrosis, retroperitoneal fibrosis, pleural fibrosis), which are not associated with non-ergoline agents.

The MHRA advises that non-ergoline dopamine agonists such as ropinirole and pramipexole should be preferred over ergoline agents for this reason.

Clinical evidence for ropinirole

Ropinirole has been evaluated in multiple large randomised controlled trials for both Parkinson's disease and restless legs syndrome.

In early Parkinson's disease, pivotal trials demonstrated that ropinirole monotherapy significantly improved motor scores on the Unified Parkinson's Disease Rating Scale (UPDRS) compared with placebo.

A landmark 5-year comparative study of ropinirole versus levodopa in early Parkinson's disease found that patients randomised to ropinirole had significantly lower rates of dyskinesia (20% versus 45%), supporting the strategy of starting with a dopamine agonist in suitable patients.

However, levodopa provided greater motor improvement overall.

In advanced Parkinson's disease, ropinirole used as adjunctive therapy alongside levodopa has been shown to reduce daily "off" time (periods when levodopa effect wears off and symptoms return) by approximately 1 to 2 hours per day.

The prolonged-release formulation (Requip XL) offers the convenience of once-daily dosing with equivalent efficacy to immediate-release ropinirole given three times daily.

For restless legs syndrome, randomised controlled trials have shown that ropinirole significantly improves symptom scores and sleep quality compared with placebo.

The TREAT RLS study group demonstrated clinically meaningful improvements in the International Restless Legs Syndrome Study Group (IRLS) rating scale with ropinirole at doses of 0.25 mg to 4 mg daily.

Ropinirole compared with other dopamine agonists

Pramipexole is the other widely used non-ergoline dopamine agonist in the UK and is licensed for both Parkinson's disease and RLS.

Ropinirole and pramipexole have similar efficacy in both conditions. The main pharmacokinetic difference is that ropinirole is hepatically metabolised (by CYP1A2), while pramipexole is renally excreted.

This means ropinirole is affected by CYP1A2 inhibitors and inducers (including smoking), while pramipexole dose must be adjusted in renal impairment.

The choice between them is often based on the prescriber's experience and the patient's comorbidities.

Rotigotine is available as a transdermal patch, which may be useful for patients who have difficulty swallowing or who prefer a non-oral formulation.

Dosage and administration

Ropinirole requires careful dose titration to minimise side effects, particularly nausea and dizziness.

For Parkinson's disease with immediate-release tablets, start at 0.25 mg three times daily and increase gradually over 4 weeks to 1 mg three times daily, then further as needed up to a maximum of 24 mg daily.

For the prolonged-release formulation, start at 2 mg once daily and increase by 2 mg per day at weekly intervals up to a maximum of 24 mg daily.

For RLS, start at 0.25 mg once daily before bedtime and titrate upward as needed to a maximum of 4 mg daily.

Do not stop ropinirole abruptly. Gradual dose reduction over 1 to 2 weeks is essential to avoid withdrawal symptoms. Take with food to reduce nausea. Prolonged-release tablets must be swallowed whole.

Side effects of ropinirole

Common side effects

Nausea is the most frequently reported side effect, occurring in approximately 40% of patients during dose titration. It usually improves over time.

Taking ropinirole with food and, if needed, using domperidone as an anti-emetic can help.

Dizziness, somnolence (excessive sleepiness), and orthostatic hypotension are also common, especially at the start of treatment and during dose increases.

Stand up slowly and sit down if you feel lightheaded.

Impulse control disorders and sleep attacks

Impulse control disorders (pathological gambling, binge eating, compulsive shopping, hypersexuality) and sudden onset of sleep are important safety concerns with all dopamine agonists, including ropinirole.

The MHRA has issued specific Drug Safety Updates on both risks.

Patients and their families must be informed about these risks before treatment starts and should report any behavioural changes promptly.

Sudden onset of sleep may occur without prior drowsiness and has been associated with road traffic accidents.

Patients who experience sleep attacks must stop driving and inform the DVLA.

Other side effects

Hallucinations (usually visual) may occur, particularly in older patients with advanced Parkinson's disease. Peripheral oedema, constipation, and abdominal pain have been reported.

Dyskinesia may develop when ropinirole is used alongside levodopa.

Augmentation (worsening of RLS symptoms, earlier onset, or spread to the arms) is a concern with long-term dopamine agonist therapy for RLS.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Driving and machine operation

Ropinirole may impair your ability to drive or operate machinery due to somnolence, dizziness, or sudden onset of sleep.

The DVLA provides guidance for drivers with Parkinson's disease and for drivers taking medicines that may cause drowsiness.

If you experience excessive sleepiness or sudden sleep attacks, you must stop driving immediately and inform the DVLA.

Drug interactions

CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) may increase ropinirole levels. Smoking induces CYP1A2 and reduces ropinirole levels.

Dopamine antagonists (antipsychotics such as haloperidol, olanzapine, quetiapine) may reduce the effectiveness of ropinirole.

Oestrogen-containing hormone replacement therapy may increase ropinirole exposure; dose adjustment may be needed if HRT is started or stopped.

Special populations

Pregnancy: ropinirole should not be used in pregnancy unless clearly necessary. It may suppress prolactin and inhibit lactation. Breastfeeding is not recommended.

Elderly: start at the low end of the dose range and titrate slowly. Hepatic impairment: use with caution, as ropinirole is extensively hepatically metabolised.

Renal impairment: no dose adjustment required for mild to moderate impairment.

How to get ropinirole in the UK

Ropinirole is available on NHS prescription from your GP, neurologist, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Generic ropinirole is widely available and commonly prescribed.

Sources

• Ropinirole tablets, Summary of Product Characteristics (EMC)
• Ropinirole, British National Formulary (BNF)
• Parkinson's disease in adults, NICE NG71
• Restless legs syndrome, NICE CKS
• Parkinson's disease, NHS
• MHRA Yellow Card Scheme